NEWPHARM S.A. - etsinnän tulokset

merck europe b.v. - kladribiini - multippeliskleroosi - immunosuppressantit - hoito aikuispotilailla, joilla on erittäin aktiivinen relapsoiva multippeliskleroosi (ms) kliinisten tai kuvantamisominaisuuksien perusteella.

Euroopan unioni - suomi - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiset aineet - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Suomi - suomi - Fimea (Suomen lääkevirasto)

cetirizin bmm pharma 1 mg/ml oraaliliuos

bmm pharma ab - cetirizini dihydrochloridum - oraaliliuos - 1 mg/ml - setiritsiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

fexofenadine bluefish 120 mg tabletti, kalvopäällysteinen

bluefish pharmaceuticals ab bluefish pharmaceuticals ab - fexofenadini hydrochloridum - tabletti, kalvopäällysteinen - 120 mg - feksofenadiini